Healthcare · NYSE/NASDAQ: PFE
PFIZER INC
Drug Manufacturers—General
Market Cap $148.19B
Verdict: Average
Quality Scores
Multi-Bagger
42/100
Compounder Quality
68/100
Management Credibility
65/100
Governance
85/100
Cash Flow Quality
72/100
AI Summary
Pfizer Inc. (PFE) has navigated an unprecedented period of volatility primarily driven by its COVID-19 franchise (Comirnaty/Paxlovid), which spiked 2022 revenues to over $100B before a sharp normalization. The company is currently in a transition phase, utilizing its pandemic windfall to fund aggressive M&A, most notably the $43B acquisition of Seagen to pivot toward oncology. While top-line scale remains massive, the earnings profile is hindered by significant R&D requirements and the upcoming loss of exclusivity on key blockbuster drugs later this decade. The balance sheet has expanded…
Top Opportunities
- Robust oncology pipeline following Seagen acquisition
- Consistent dividend payer with high yield
- Strong historical presence and brand equity
Top Risks
- Sharp decline in COVID-19 franchise revenue
- LOE (Loss of Exclusivity) risks for key drugs mid-decade
- High volatility in net income margins
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.